Jay Olson Analyst Performance

Jay Olson is a stock analyst at Oppenheimer focused in the medical sector, covering 53 publicly traded companies. Over the past year, Jay Olson has issued 20 stock ratings, including buy and hold recommendations. While full access to Jay Olson's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Jay Olson's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Analyst Ranking

Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat

Average Return

00.00% 12-Month ROI

Success Rate

00.00% Profitable Ratings

Total Ratings

417 Last 10 Years

Buy Recommendations

79.75% 323 Buy Ratings

Companies Covered

53 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	79.8%	323 ratings
Hold	19.5%	79 ratings
Sell	0.7%	3 ratings

Out of 405 total stock ratings issued by Jay Olson at Oppenheimer, the majority (79.8%) have been Buy recommendations, followed by 19.5% Hold and 0.7% Sell.

Best & Worst Calls

• Best Call

  0000.0%

  CBAY

  Mar 2020

  Subscribe to MarketBeat All Access to get analyst recommendation ROI.
• Worst Call

  000.0%

  NTEC

  Feb 2019

  Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	100.0% of companies on NASDAQ	53 companies

Jay Olson, an analyst at Oppenheimer, currently covers 53 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 51 companies	96.2%
	Aerospace 1 company	1.9%
	Miscellaneous 1 company	1.9%

Jay Olson of Oppenheimer specializes in stock coverage within the Medical sector, with additional focus on Aerospace and companies.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 24 companies	45.3%
PHARMACEUTICAL PREPARATIONS 11 companies	20.8%
MED - DRUGS 8 companies	15.1%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC 4 companies	7.5%
BIOTECHNOLOGY 3 companies	5.7%
MED - OUTP/HM CRE 1 company	1.9%
AEROSP/DEF EQ 1 company	1.9%
Miscellaneous 1 company	1.9%

Jay Olson's Ratings History at Oppenheimer

Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe

Start Date

End Date

All Ratings Strong Buy Buy Hold Sell Rating

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription

12-Month ROIUpgrade to All Access to use the All ROI Filter

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating	12-Month Price & ROI	Details
IMRX Immuneering	9/25/2025	Boost Price Target	$8.36	$30.00	Outperform	$0.00 00.00% ROI
BCYC Bicycle Therapeutics	8/11/2025	Reiterated Rating	$7.59	$44.00	Outperform	$0.00 00.00% ROI
MNMD Mind Medicine (MindMed)	8/4/2025	Initiated Coverage	$8.44	$25.00	Outperform	$0.00 00.00% ROI
ATAI atai Life Sciences	7/29/2025	Initiated Coverage	$3.33	$14.00	Outperform	$0.00 00.00% ROI
PRAX Praxis Precision Medicines	7/8/2025	Boost Price Target	$46.39	$115.00	Outperform	$0.00 00.00% ROI
PRAX Praxis Precision Medicines	6/2/2025	Set Price Target	$37.82	$97.00	Outperform	$0.00 00.00% ROI
PRTA Prothena	5/27/2025	Downgrade	$6.58		Market Perform	$0.00 00.00% ROI
TVRD Tvardi Therapeutics	5/21/2025	Initiated Coverage	$29.09	$65.00	Outperform	$0.00 00.00% ROI
JSPR Jasper Therapeutics	5/15/2025	Lower Price Target	$4.88	$65.00	Outperform	$0.00 00.00% ROI
INO Inovio Pharmaceuticals	5/14/2025	Lower Price Target	$1.86	$13.00	Outperform	$0.00 00.00% ROI
RVMD Revolution Medicines	5/8/2025	Boost Price Target	$42.56	$75.00	Outperform	$0.00 00.00% ROI
IMRX Immuneering	5/7/2025	Lower Price Target	$1.18	$21.00	Outperform	$0.00 00.00% ROI
BIIB Biogen	5/2/2025	Set Price Target	$121.80	$205.00		$0.00 00.00% ROI
NKTR Nektar Therapeutics	3/14/2025	Upgrade	$12.23	$90.00	Outperform	$0.00 00.00% ROI
DNLI Denali Therapeutics	3/3/2025	Lower Price Target	$15.46	$42.00	Outperform	$0.00 00.00% ROI
PRTA Prothena	2/7/2025	Boost Price Target	$13.93	$62.00	Outperform	$0.00 00.00% ROI
EXEL Exelixis	1/24/2025	Downgrade	$34.13	$33.00	Market Perform	$0.00 00.00% ROI
EXEL Exelixis	1/16/2025	Boost Price Target	$36.81	$41.00	Outperform	$0.00 00.00% ROI
NTLA Intellia Therapeutics	1/13/2025	Lower Price Target	$9.99	$40.00	Outperform	$0.00 00.00% ROI
GLTO Galecto	10/17/2024	Boost Price Target	$6.71	$10.00	Outperform	$0.00 00.00% ROI

Stock Forecasts and Research Tools

Sign in to your free account to enjoy these benefits

• In-depth profiles and analysis for 20,000 public companies.
• Real-time analyst ratings, insider transactions, earnings data, and more.
• Our daily ratings and market update email newsletter.

Sign in to your free account to enjoy all that MarketBeat has to offer.

• Sign In
• Create Account

Your Email Address:

Email Address Required

Your Password:

Password Required

Log In

---

or

Sign in with Facebook Sign in with Google

Forgot your password?

Your Email Address:

Please enter your email address.

Please enter a valid email address

Choose a Password:

Please enter your password.

Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character.

Create My Account (Free)

---

or

Sign in with Facebook Sign in with Google

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.